ongericimab 
GtoPdb Ligand ID: 13787
|
Synonyms: JS-002 | JS002 | Junshida®
ongericimab is an approved drug
Compound class:
Antibody
Comment: Ongericimab (JS002) is a subcutaneous humanized anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody [1]. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol (LDL-C) from the circulation. Ongericimab was developed for patients at high risk for cardiovascular disease, as an add-on treatment when standard lipid-lowering therapy fails to achieve LDL-C target level.
|
| Bioactivity Comments |
| We have been unable to find quantitative data for the binding of the antibody to its primary target. |
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License